Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition
- 26 June 2018
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 38 (9) , 1699-1704
Abstract
The efficacy of tocilizumab (TCZ), a monoclonal antibody to the interleukin (IL)-6 receptor, in suppressing disease activity in glucocorticoid-naïve patients with new-onset polymyalgia rheumatica (PMR) was studied. Its effect on a panel of cytokines and growth factors was evaluated. Three patients, fulfilling the PMR ACR/EULAR criteria, received TCZ at the dosage of 8 mg/kg every 4 weeks for three times followed by prednisone 0.2 mg/kg in case of inefficacy. Concentrations of IL-10, IL-6, tumour necrosis factor (TNF)-α, IL-1β, IL-10, IL-17, interferon (IFN)-γ, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and leukaemia inhibitory factor (LIF) were measured at baseline, after 72 h of the first TCZ infusion and then at weeks 1, 4, 5, 8, 9, 12, 13, 14, 16, and 22. A slight clinical improvement was seen only after the first TCZ infusion, but was largely inferior to that of conventional doses of GC administered subsequently. An ischaemic visual accident suggestive of GCA occurred in one patient during TCZ treatment. IL-6 was increased at baseline compared to controls, further increased after the first TCZ infusion, and was suppressed by GC. IL-17 production decreased during TCZ treatment and reverted to pre-treatment levels after GC. VEGF e PDGF showed a less constant pattern, but an increase of VEGF concentration antedated visual symptoms. The other cytokines were not detectable in patients and controls. In our small sample, TCZ was not able to suppress inflammation at the same degree as GC. As a result, monotherapy with TCZ in PMR cannot be recommended, although its efficacy as adjunctive treatment in GC-resistant patients should be further evaluated.Keywords
This publication has 18 references indexed in Scilit:
- Trial of Tocilizumab in Giant-Cell ArteritisNew England Journal of Medicine, 2017
- Brief Report: A Prospective Open‐Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia RheumaticaArthritis & Rheumatology, 2016
- Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumaticaRheumatology, 2015
- Tocilizumab for polymyalgia rheumatica: Report of two cases and review of the literatureSeminars in Arthritis and Rheumatism, 2013
- Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumaticaArthritis Care & Research, 2012
- Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosisRheumatology, 2011
- Polymyalgia rheumatica and giant-cell arteritisThe Lancet, 2008
- Vascular endothelial growth factor production in polymyalgia rheumaticaArthritis & Rheumatism, 2000
- A study of the Health Assessment Questionnaire to evaluate functional status in polymyalgia rheumaticaRheumatology, 2000
- Formation of New Vasa Vasorum in VasculitisThe American Journal of Pathology, 1999